Logo image of DXR

DAXOR CORP (DXR) Stock Fundamental Analysis

NASDAQ:DXR - Nasdaq - US2394671034 - Common Stock - Currency: USD

7.7001  +0.14 (+1.85%)

Fundamental Rating

2

Taking everything into account, DXR scores 2 out of 10 in our fundamental rating. DXR was compared to 188 industry peers in the Health Care Equipment & Supplies industry. DXR may be in some trouble as it scores bad on both profitability and health. DXR has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year DXR was profitable.
In the past year DXR has reported a negative cash flow from operations.
In multiple years DXR reported negative net income over the last 5 years.
DXR had negative operating cash flow in 4 of the past 5 years.
DXR Yearly Net Income VS EBIT VS OCF VS FCFDXR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5M -5M 10M 15M

1.2 Ratios

The Return On Assets of DXR (4.91%) is better than 83.33% of its industry peers.
DXR's Return On Equity of 5.17% is fine compared to the rest of the industry. DXR outperforms 78.49% of its industry peers.
Industry RankSector Rank
ROA 4.91%
ROE 5.17%
ROIC N/A
ROA(3y)12.3%
ROA(5y)4.62%
ROE(3y)13.7%
ROE(5y)5.26%
ROIC(3y)N/A
ROIC(5y)N/A
DXR Yearly ROA, ROE, ROICDXR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 -40 -60

1.3 Margins

With an excellent Profit Margin value of 1093.32%, DXR belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
DXR does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) 1093.32%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DXR Yearly Profit, Operating, Gross MarginsDXR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 1K 2K

More info and screens

3

2. Health

2.1 Basic Checks

DXR has more shares outstanding than it did 1 year ago.
The number of shares outstanding for DXR has been increased compared to 5 years ago.
DXR has a better debt/assets ratio than last year.
DXR Yearly Shares OutstandingDXR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M 4M
DXR Yearly Total Debt VS Total AssetsDXR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M

2.2 Solvency

DXR has an Altman-Z score of 13.82. This indicates that DXR is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 13.82, DXR belongs to the top of the industry, outperforming 93.55% of the companies in the same industry.
A Debt/Equity ratio of 0.05 indicates that DXR is not too dependend on debt financing.
DXR's Debt to Equity ratio of 0.05 is fine compared to the rest of the industry. DXR outperforms 63.44% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z 13.82
ROIC/WACCN/A
WACCN/A
DXR Yearly LT Debt VS Equity VS FCFDXR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10M 20M 30M

2.3 Liquidity

DXR has a Current Ratio of 0.01. This is a bad value and indicates that DXR is not financially healthy enough and could expect problems in meeting its short term obligations.
DXR has a Current ratio of 0.01. This is amonst the worse of the industry: DXR underperforms 98.92% of its industry peers.
DXR has a Quick Ratio of 0.01. This is a bad value and indicates that DXR is not financially healthy enough and could expect problems in meeting its short term obligations.
DXR has a worse Quick ratio (0.01) than 98.92% of its industry peers.
Industry RankSector Rank
Current Ratio 0.01
Quick Ratio 0.01
DXR Yearly Current Assets VS Current LiabilitesDXR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M 4M

More info and screens

0

3. Growth

3.1 Past

DXR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -60.74%.
DXR shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -14.28%.
Measured over the past years, DXR shows a very negative growth in Revenue. The Revenue has been decreasing by -17.59% on average per year.
EPS 1Y (TTM)-60.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%54.9%
Revenue 1Y (TTM)-14.28%
Revenue growth 3Y-14.34%
Revenue growth 5Y-17.59%
Sales Q2Q%-10.25%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
DXR Yearly Revenue VS EstimatesDXR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 500K 1M 1.5M 2M
DXR Yearly EPS VS EstimatesDXR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 0.02 0.04 0.06 0.08

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 22.65, which indicates a rather expensive current valuation of DXR.
Compared to the rest of the industry, the Price/Earnings ratio of DXR indicates a rather cheap valuation: DXR is cheaper than 82.80% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of DXR to the average of the S&P500 Index (29.75), we can say DXR is valued slightly cheaper.
Industry RankSector Rank
PE 22.65
Fwd PE N/A
DXR Price Earnings VS Forward Price EarningsDXR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DXR Per share dataDXR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for DXR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DAXOR CORP

NASDAQ:DXR (3/3/2025, 8:28:00 PM)

7.7001

+0.14 (+1.85%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-29 2024-02-29/amc
Earnings (Next)N/A N/A
Inst Owners2.3%
Inst Owner Change20.02%
Ins Owners5.35%
Ins Owner Change1.38%
Market Cap37.27M
Analysts80
Price Target23.84 (209.61%)
Short Float %0.6%
Short Ratio1.86
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.03
Dividend Growth(5Y)-31.9%
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 22.65
Fwd PE N/A
P/S 241.53
P/FCF N/A
P/OCF N/A
P/B 1.14
P/tB 1.14
EV/EBITDA N/A
EPS(TTM)0.34
EY4.42%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.35
FCFYN/A
OCF(TTM)-0.35
OCFYN/A
SpS0.03
BVpS6.75
TBVpS6.75
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 4.91%
ROE 5.17%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 1093.32%
GM N/A
FCFM N/A
ROA(3y)12.3%
ROA(5y)4.62%
ROE(3y)13.7%
ROE(5y)5.26%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.01
Quick Ratio 0.01
Altman-Z 13.82
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-60.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%54.9%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-14.28%
Revenue growth 3Y-14.34%
Revenue growth 5Y-17.59%
Sales Q2Q%-10.25%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y27.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y12.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y12.55%
OCF growth 3YN/A
OCF growth 5YN/A